Orgenesis

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

GERMANTOWN, Md., June  10, 2020  (GLOBE NEWSWIRE) --   Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announces the launch of its BioShield Program, which is designed to accelerate the potential discovery and validation of neutralizing human antibodies as a possible rapid defense of the population and to potentially mitigate the spread of viruses such as COVID-19.  The goal of the BioShield Program is to increase the level of preparedness to fight against emerging outbreaks and help avoid a global pandemic.

Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Virus Spread and Protect Against Future Outbreaks such as COVID-19

GERMANTOWN, Md., June  01, 2020  (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs) while lowering costs, today announces that it has entered into a Clinical Study Agreement with The Edith Wolfson Medical Center, a leading public hospital in Israel. Under the agreement, the parties will conduct a clinical study with a goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including a novel, automated cell culturing system, designed to enable a faster, safer and metabolically optimized culturing and expansion process for the generation and expansion tumor infiltrating lymphocytes (TIL) for use in adoptive T-cell therapies.

Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of Tumor Infiltrating Lymphocytes

Collaboration project focused on clinical development and validation of Orgenesis’ immune-oncology cell therapies Collaboration project focused on clinical development and validation of Orgenesis’ immune-oncology cell therapies

Orgenesis Announces Collaboration with Hospital Infantil Universitario Niño Jesús, Madrid, to Establish Point of Care Center

GERMANTOWN, Md., May  15, 2020  (GLOBE NEWSWIRE) --   Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs) while lowering costs, announces that its Board of Directors has authorized a repurchase plan (the “Repurchase Plan”) of up to $10 million of the Company’s common stock from time to time on the open market or in privately negotiated block transactions.

Orgenesis Announces Stock Repurchase Plan of Up to $10 Million

Orgenesis (NASDAQ: ORGS) shares are trading higher on Wednesday. The company announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases.

Why Orgenesis Stock Is Trading Higher Today

Initiating a novel program targeting the virus and virus infected cells, using whole cell-based vaccines Initiating a novel program targeting the virus and virus infected cells, using whole cell-based vaccines

Orgenesis Announces Cell-Based Vaccine Platform Targeting COVID-19 and other Existing and Emerging Viral Diseases

Cash and cash equivalents of $107.1 million as of March 31, 2020 Cash and cash equivalents of $107.1 million as of March 31, 2020

Orgenesis First Quarter 2020 Revenue Increases 348% to $1.9 Million Reflecting Success of CGT Biotech Platform

GERMANTOWN, Md., April  29, 2020  (GLOBE NEWSWIRE) --  Orgenesis Inc  . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs) while lowering costs, announces that The Medicine Maker Power List 2020 has ranked Vered Caplan, CEO of Orgenesis, as one of the world’s top 20 inspirational leaders in the field of advanced medicine.

Orgenesis CEO Vered Caplan Recognized Among World's Top 20 Inspirational Leaders in Advanced Medicine in The Medicine Maker 'Power List 2020'

GERMANTOWN, Md., April  27, 2020  (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs) while lowering costs, announces it has completed acquiring the assets of Tamir Biotechnology, Inc. (“TamirBio”), including ranpirnase, TamirBio’s broad spectrum anti-viral platform. The acquisition included total stock and cash consideration of approximately $21 million, based on the value of the stock at closing.

Orgenesis Completes Acquisition of Tamir Biotechnology, Inc. Assets Including Broad Spectrum Antiviral Platform

Pluristem Therapeutics

Teladoc

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma

Strategy to combine ranpirnase antiviral platform with Bioxome™ technology Strategy to combine ranpirnase antiviral platform with Bioxome™ technology

Orgenesis Announces Agreement to Acquire Assets of Tamir Biotechnology, Inc.  Including Broad Spectrum Antiviral Platform

JV to utilize RevaTis’s patented technique to obtain mdMSCs through a minimally invasive muscle biopsy and leverage mdMSC manufacturing capability

Orgenesis Announces Joint Venture Agreement with RevaTis to Produce Muscle-Derived Mesenchymal Stem Cells (mdMSC) as a Source of Exosomes and Other Cellular Products for the Development of Related Therapies

Patented process results in uniform, scalable production and ability to deliver cell cargo similar to natural exosomes/EVs Patented process results in uniform, scalable production and ability to deliver cell cargo similar to natural exosomes/EVs

Orgenesis and ExcellaBio Announce Breakthrough Manufacturing Process for Bioxomes™,  Proprietary Synthetic Exosomes/Extracellular Vesicles (EV)

GERMANTOWN, Md., March  30, 2020  (GLOBE NEWSWIRE) --   Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies (CGTs), provides the following letter to its shareholders from CEO Vered Caplan:

Orgenesis CEO Vered Caplan Provides Letter to Shareholders

GERMANTOWN, Md., Feb.  19, 2020  (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopkins University (“JHU”) to utilize Orgenesis’ POCare platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies. 

Orgenesis Announces Collaboration with The John Hopkins University for the Development and Processing of Cell and Gene Based Clinical Therapeutics

GERMANTOWN, Md., Feb.  03, 2020  (GLOBE NEWSWIRE) --   Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Global, Inc., a contract development manufacturing organization (CDMO) subsidiary of Orgenesis backed by Great Point Partners and SFPI-FPIM. Orgenesis anticipates that it will receive proceeds of approximately $127 million resulting from the transaction. The transaction is expected to close during the current fiscal first quarter of 2020. Orgenesis expects to use the net proceeds from the sale of Masthercell to continue to grow its point-of-care cell therapy business and to further the development of Advanced Therapy Medicinal Products. Additional details on the transaction will be available in the Company’s Current Report on Form 8-K filed today with the Securities and Exchange Commission at  www.sec.gov  and on the Company’s website at:  https://ir.orgenesis.com/all-sec-filings .

Orgenesis Announces Agreement for the Sale of Masthercell Global, its Contract Development and Manufacturing Organization (CDMO) Subsidiary

GERMANTOWN, Md., Jan.  21, 2020  (GLOBE NEWSWIRE) --  Orgenesis Inc  .  (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized point-of-care development and processing centers, announced today that it has entered into a definitive securities purchase agreement with certain institutional investors, including The Phoenix Insurance Company Ltd. and Sphera Global Healthcare Master Fund, for the sale of 2,200,000 shares of the Company’s common stock in a private placement at a purchase price of $4.20 per share and warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $5.50 per share. The warrants are not exercisable until after six months and expire three years from the date of issuance. The Company expects to receive gross proceeds of approximately $9,240,000 before deducting related offering expenses. The Company intends to use the proceeds of this financing to expand its point-of-care (POCare) cell-therapy platform, which is designed to collect, process and supply therapeutic cells within the patient care setting for various treatments, as well as for general corporate purposes. The offering is expected to close on or about January 23, 2020, subject to customary closing conditions.

Orgenesis Inc. Announces $9.2 Million Private Placement

First collaboration project focused on developing and commercializing lentiviral manufacturing system First collaboration project focused on developing and commercializing lentiviral manufacturing system

Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis’ Point of Care Platform for the Development, Commercialization and Supply of Cell and Gene Therapy Products

Milestone Payment from Great Point Partners Marks Second and Final Payment of its $25 Million Planned Investment Milestone Payment from Great Point Partners Marks Second and Final Payment of its $25 Million Planned Investment

Orgenesis Announces Receipt of the $6.6 Million Second Milestone Payment into Masthercell Global Subsidiary

Partnership to enable HYGEIA’s hospital network to develop and deliver onsite cell and gene therapies to patients Partnership to enable HYGEIA’s hospital network to develop and deliver onsite cell and gene therapies to patients

Orgenesis and Theracell to Launch Point of Care Cell and Gene Therapy Centers within HYGEIA Group’s Hospital Network in Greece

GERMANTOWN, Md., Nov.  26, 2019  (GLOBE NEWSWIRE) --   Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers, today announced it has been ranked the 5th fastest growing technology company in Maryland and 208th in North America on Deloitte’s 2019 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Orgenesis’ revenue increased 527% during the period from 2015 to 2018.

Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on Deloitte's 2019 Technology Fast 500™

GERMANTOWN, Md., Nov.  22, 2019  (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers, today reminds those stockholders that have not yet voted to vote without delay “FOR” all proposals as disclosed in the Company’s proxy statement for the annual meeting of stockholders to be held on November 26, 2019 at 10:00 a.m. Eastern Time.

Orgenesis Inc. Reminds Stockholders to Vote in Favor of All Proposals at the Annual Meeting of Stockholders to be Held on November 26, 2019

GERMANTOWN, Md., Nov.  13, 2019  (GLOBE NEWSWIRE) --   Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers, today announced that Vered Caplan, CEO of Orgenesis, appeared as a guest during the “Israel Business Weekly” segment hosted by Michelle Makori and Eric Landskroner on the i24News Network. Vered Caplan discussed how she believes that Orgenesis is transforming the cell and gene therapy market and lowering costs to deliver potentially life-saving therapies to patients.

Orgenesis CEO Appears as a Guest on i24 News Network

Generates over $1 million in sales through new POCare platform Generates over $1 million in sales through new POCare platform

Orgenesis Third Quarter 2019 Revenue Increases 46% to a Record $9.1 Million

Appointment adds innovation and optical technology skills to advance cell and gene therapy capabilities Appointment adds innovation and optical technology skills to advance cell and gene therapy capabilities

News for Orgenesis Stock (ORGS)